The agreement continues the flurry of deal-making in the health care industry, as companies seek to buy the growth they are hard-pressed to generate on their own. Announced merger volume in the sector this year is up 14% from the period a year earlier, even as takeovers have fallen 8%.
This acquisition follows Valeant's April purchase for Obagi skin care for $348 million.
Follow Happi On